Trials / Completed
CompletedNCT03070301
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEE011 | LEE011 200 mg daily |
| DRUG | everolimus | everolimus 5 mg daily or 2.5mg daily |
Timeline
- Start date
- 2017-02-27
- Primary completion
- 2024-01-31
- Completion
- 2024-01-31
- First posted
- 2017-03-03
- Last updated
- 2024-10-10
- Results posted
- 2024-10-10
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03070301. Inclusion in this directory is not an endorsement.